Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu). The oral tyrosine kinase inhibitors (TKI) dasatinib, imatinib, ponatinib, nilotinib and bosutinib each target BCR-ABL, yet are structurally distinct from one another. [1] [2] [3] [4] [5] [6] The selection of BCR-ABL TKI treatment for an individual patient is influenced by factors including any previous treatment, likelihood of benefit, risk of toxicities and the potential for end-organ damage resulting from use, particularly as a long-term therapy is expected in chronic myeloid leukemia in chronic phase (CML-CP). Despite considerable overlap of safety profiles, there are distinct drug-specific adverse events associated with each TKI. 2 Peripheral arterial disease (PAD) is often associated with claudication, and may result in critical limb ischemia, and increased risks of loss of limb or death. 7 We evaluated safety databases of dasatinib clinical trials in patients with Philadelphia chromosome-positive (Ph+) leukemias to identify PAD or PADrelated events. We also conducted a standardized incidence ratio (SIR) analysis to evaluate the rate of PAD or PAD-related events in the trials relative to the rate in external reference populations derived from administrative data sets, representing a general adult population in the United States and a CML population that did not receive dasatinib. This retrospective analysis used pooled safety data from 2712 adults with CML or Ph+ acute lymphoblastic leukemia (ALL) treated with dasatinib in 11 clinical trials, including two first-line trials (n = 324) and nine trials in imatinibresistant or -intolerant patients (n = 2388; Supplementary Table  S1 ). The median duration of dasatinib treatment was 19 months (range: 0.03-93 months). The trial enrollment criteria permitted inclusion of patients with myocardial infarction 46 months prior, congestive heart failure 43 months prior and previously uncontrolled angina controlled ⩾ 3 months.
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Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials
Bristol-Myers Squibb safety databases for the included trials were examined to identify PAD or PAD-related events, using the following Medical Dictionary for Regulatory Activities preferred terms: arterial stenosis, arterial thrombosis, arteriosclerosis, arterial stenosis limb, intermittent claudication, femoral artery occlusion, necrosis ischemic and PAD.
For the SIR analysis (SIR = observed number of events/expected number of events; detailed description in Supplementary Materials), two external populations were extracted from Truven Health Analytics Marketscan Commercial Claims and Medicare Supplementary database (Ann Arbor, MI, USA) between 2008 and 2013. MarketScan consists of data from commercial health plans, Medicaid, Medicare, and self-insurance for Americans. Each reference population included individuals enrolled in the databases for ⩾ 60 days before the index date. Adult patients were included in the general reference population (n = 90 000 000), and the CML reference population had ⩾ 2 diagnostic codes for CML and were not using dasatinib (n = 15 000). To obtain the expected number of cases, the age and gender-specific person-time of dasatinib-treated patients in the trials were multiplied by the age and gender-specific rates of events in the external populations.
PAD or PAD-related events were detected in 11 patients during dasatinib treatment among 2712 individuals with a cumulative dasatinib exposure of 6421 patient-years, which corresponds to a cumulative incidence of 0.4% and an incidence rate (per 100 patient-years) of 0.2%. Of the 11 patients, all were previously treated with a TKI; 8 were resistant and 3 were intolerant to prior imatinib therapy ( The chronic phase disease of this patient had clonal evolution.
Letters to the Editor Table 1 . For these patients, median age at baseline was 68 years (range: 44-80 years) and median duration of dasatinib before diagnosis of PAD or PAD-related event was 777 days (range: 3-2227 days). Median duration of prior imatinib therapy amongst these patients was 29 months (n = 9; range: 2-74 months). Of the 11 patients, 8 had CML-CP, 2 had CML in accelerated phase (CML-AP) and one had CML in blast phase (CML-BP) of lymphoid phenotype. Ten of the 11 patients were on BID (twice daily) dosing regimens. Of the eight patients with CML-CP, only one started at a dose of 100 mg QD (once daily), the current recommended dose of dasatinib for CML-CP. 2 Dosing regimens for the other seven patients with CML-CP ranged from 25 to 70 mg BID. The current recommended dose for CML-AP or CML-BP is 140 mg QD; 2 however, the patients with CML-AP (n = 2) and CML-BP (n = 1) received a 70 mg BID starting dose of dasatinib.
All 11 patients had pre-existing comorbidities/conditions that potentially increased the risk of developing PAD (Table 1) , including one patient who had prior arterial bypass surgery, one with a history of angioplasty and stent, and one who had pre-existing PAD. Furthermore, six patients had hypertension, four had pre-existing ischemic heart disease, four were former or current smokers, two had pre-existing noncardiac atherosclerosis, two had hypercholesterolemia, two had diabetes mellitus and one had deep vein thrombosis (DVT). Of nine patients with PAD or a PAD-related event with available data, all were receiving other medications at baseline. The PAD or PAD-related events in the 11 cases included intermittent claudication (four patients), femoral artery occlusion (two patients), PAD (two patients), peripheral ischemia (two patients), peripheral artery thrombosis (one patients) and peripheral vascular disorder (one patient), with one patient experiencing two of these events (Table 1 ). All events identified were Common Terminology Criteria grade ⩽ 3. Of seven patients with available molecular response data, best responses at any time included 27% (n = 3) with a major molecular response, 18% (n = 2) achieving complete molecular response (CMR 4.5 ) and 36% (n = 4) achieving a complete cytogenetic response. Dasatinib treatment was interrupted in five patients due to PAD or a PAD-related event, and no patients discontinued dasatinib because of PAD or PAD-related events (Table 1) .
SIR analysis showed that the observed number of PAD or PADrelated events (n = 11) in the pooled population did not exceed the expected number of events (n = 20) in the general population (SIR (95% confidence interval; CI), 0.56 (0.31-1.01)). Similarly, the observed number of PAD or PAD-related events (n = 11) in the pooled population did not exceed the expected number (n = 43) based on rates in the reference CML population (SIR (95% CI), 0.26 (0.14-0.46); Supplementary Table S2) .
The current analysis investigated the incidence of PAD or PADrelated events in patients treated with dasatinib to test the hypothesis that PAD might be a class effect among second-and third-generation BCR-ABL TKIs. Previous reports have described an association of PAD with either ponatinib or nilotinib treatment. 4, 5 The cumulative incidence and incidence rate (per 100 patientyears) reported here are higher than those previously published in a retrospective analysis by Giles and colleagues for imatinib (0.2% and 0.1%, respectively); however, they are lower than cited for nilotinib (1.3% and 0.5%, respectively) and interferon-α plus cytarabine (0.6% and 0.6%, respectively; Table 2 ). 8 No PAD or PAD-related events were identified in newly diagnosed CML patients treated with dasatinib in the DASISION trial, which has the longest median exposure time to dasatinib of any study.
Generally, risk factors for cardiovascular disease are also risk factors for PAD or PAD-related events. 7, 9 The prevalence of PAD increases with age and concomitant cardiovascular disease risk factors. 8, 10 Some clinical trials report a lower incidence of PAD in CML and Ph+ ALL compared with published rates for the general population; however, this may be affected by the study entry criteria that exclude patients with significant cardiovascular disease. 7, 8, 9, 11 The included dasatinib clinical trials (with the exception of CA180-002) allowed the participation of patients with diabetes and patients with a history of cardiac comorbidities. Ten of the 11 patients with PAD or PAD-related events had at least one potential risk factor for PAD (the remaining patient had DVT).
The extended survival of CML patients in the TKI era makes it important to understand the implications of long-term treatment and understand better the potentially irreversible and severe toxicities of some TKIs. The results presented here do not show an association between dasatinib treatment and development of symptomatic PAD in patients with CML or Ph+ ALL, and are consistent with the hypothesis that PAD observed in CML patients is not a class effect of second-and thirdgeneration BCR-ABL TKIs. Similar analyses evaluating cardiac and cerebrovascular adverse events in CML patients treated with BCR-ABL TKIs are warranted, based on the findings by ChaiAdisaksopha et al. 12 Second-generation TKIs, including dasatinib, have established higher rates of molecular remission in CML than reported with imatinib, with the hope for cure or at Includes newly diagnosed CML-CP (n = 324) and imatinib-resistant or -intolerant CML (any phase) and Ph+ ALL (n = 2388). In Giles et al, 7 PAD included atherosclerotic and thrombotic events, excluding functional (vasoreactive), embolic or aneurysmal disorders, in the arteries of lower and upper extremities. Terms indicative of PAD included: arterial disorder, peripheral ischemia, arterial insufficiency, arteriosclerosis obliterans, peripheral vascular disorder, arterial occlusive disease, femoral arterial stenosis, arterial stenosis, femoral artery occlusion, peripheral artery angioplasty, arterial stenosis limb, intermittent claudication, peripheral revascularization, arterial thrombosis limb and PAD. 8 c Patients treated with IFN+Ara-C had shorter median duration of therapy (8 months) compared with nilotinib (36 months) and imatinib (45 months) cohorts, because of early crossover to imatinib.
Letters to the Editor least treatment-free remissions. When selecting treatment for Ph+ leukemia, physicians should carefully assess overall cardiovascular health, as well as pre-existing comorbidities and risk factors present at baseline.
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